This month marks the two-year anniversary of 23andMe’s collaboration with GlaxoSmithKline (GSK).
The agreement gives Almirall the license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine
Multi-year collaboration expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programs
Anne Wojcicki discusses how 23andMe is becoming a player in medical research for age-old genetic diseases
The last year has taught most of us working today lessons usually learned over many years on the job, such as the importance of adaptability, the need to pick up...
The post Introducing 23andMe’s 2021 Summer Interns, Part I appeared first on 23andMe Blog.
23andMe’s CEO and Co-founder Anne Wojcicki rang the opening bell on Nasdaq Thursday morning, celebrating our first day as a publicly-traded company. Anne took a moment during the virtual bell-ringing...
The post Ringing in 23andMe’s Next Chapter appeared first on 23andMe Blog.
Tom Chaney was the kind of cop who was married to his job. During his more than two decades in law enforcement, he’d grab shifts on holidays, fill in for...
The post A Father and Daughter Meet for the First Time appeared first on 23andMe Blog.
23andMe joined over 100 other companies, to stand up for equity and against state legislation that discriminates against the LGBTQ+ community. The Human Rights Campaign released a statement condemning this...
The post 23andMe Signs Business Statement on Anti-LGBTQ+ State Laws appeared first on 23andMe Blog.